TrialNerd_Beth said:

LabKate said: ...compounded vs brand cost and coverage...

Financial impact of cost and coverage weight loss beyond medication cost:

• Groceries: SAVED $226/month (eating less)
• Restaurants: SAVED $216/month (fewer meals out)
• Alcohol: SAVED $166/month (stopped drinking)
• Life insurance: Premium REDUCED by $36/month (lower BMI)
• Copays: SAVED $76/month (fewer BP/cholesterol meds)

Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.

Dr.SurgeonPGH said:

Insurance update relevant to cost and coverage: I just got my prior auth approved through Aetna after 4 attempts.

This answered a question I did not know how to ask. I will report back once I have actually tried it.

TrialNerd_Beth said:

LabKate said: ...compounded vs brand cost and coverage...

TrialNerd_Beth said:

...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

1. Document medical necessity (BMI, comorbidities, failed alternatives)
2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
4. Request peer-to-peer review between your doctor and the plan's medical director
5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

hyun_seoul said:

The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…

hyun_seoul said:

...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again.